BVX 001
Alternative Names: BVX 100 vcMMAE; BVX 100-valine-citrulline-monomethylauristatin E; BVX-001Latest Information Update: 17 Feb 2025
At a glance
- Originator BiVictriX Therapeutics
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 07 Dec 2024 Pharmacodynamics and adverse event data from a preclinical study in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (Parenteral)
- 22 Jul 2020 BVX 001 is available for licensing as of 22 Jul 2020. https://www.bivictrix.com/